| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A patent landscaping of medicinal plants extracts |
0 |
0 |
0 |
0 |
1 |
3 |
6 |
97 |
| Analyse sectorielle, technologique et économique, du marché des médicaments orphelins |
0 |
0 |
0 |
0 |
1 |
1 |
6 |
42 |
| Angiogenesis inhibitors drug pipeline landscape |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
30 |
| Approche quantitative de la diffusion d’un innovation: exemple de la radiologie interventionnelle |
0 |
0 |
0 |
0 |
5 |
6 |
11 |
50 |
| Assessment of generic competition for Orphan Drugs marketed in the US (1993-2019) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
| Atelier "Accès à l'innovation" |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
7 |
| Beyond health security dependencies. Rethinking public health and industrial policies construction |
0 |
0 |
2 |
7 |
0 |
2 |
7 |
33 |
| Biodiversity Sustainability of Phytomedicine Research: a 3-dimensions analysis around the North-South divide |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
19 |
| Building an orphan drug market database to enpower decision making by patient organizations & pharma-biotech companies |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
16 |
| CH2 Une demande structurée par les prescripteur & CH3 Un système dominé par les firmes multinationales pharmaceutiques |
0 |
0 |
0 |
0 |
3 |
3 |
5 |
18 |
| Charles Dotter & the birth of Interventional Radiology: A sleeping beauty with a restless sleep |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
32 |
| Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS) |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
45 |
| Construction of mental health categories |
0 |
0 |
0 |
3 |
2 |
2 |
6 |
35 |
| Construction politique des marchés et politiques des prix. Le cas de l'industrie pharmaceutique |
0 |
0 |
0 |
0 |
2 |
4 |
8 |
95 |
| Delayed Recognition in Science: Different Causes of Sleeping and Awakening of Discoveries |
0 |
0 |
0 |
0 |
0 |
2 |
7 |
45 |
| Diagnostic prénatal non invasif sur sang maternel & Propriété Intellectuelle: entre éthique de la santé et efficience du marché |
0 |
0 |
0 |
0 |
2 |
3 |
4 |
24 |
| Diffusion of Interventional Radiology and Health Technology Assessment: the case of radiofrequency treatment in oncology |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
13 |
| Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ? |
0 |
0 |
0 |
0 |
1 |
2 |
6 |
64 |
| Does scientific knowledge play a role in public policies? A contribution of scientometrics to political science: the case of HTA |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
6 |
| Drug Safety scientometrics overview highlights public health issues |
0 |
0 |
0 |
0 |
4 |
4 |
5 |
38 |
| Drug shortages, APIs supply & Pharma Global Value Chain |
0 |
0 |
0 |
0 |
8 |
17 |
41 |
140 |
| Economie de la santé: les médicaments orphelins |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
13 |
| Empirical Economic Analysis of Orphan Drug Innovation |
0 |
0 |
0 |
0 |
2 |
2 |
2 |
13 |
| Empirical Economic Analysis of Orphan Drug Innovation |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
22 |
| Empirical Economic Analysis of Orphan Drug Innovation |
0 |
0 |
0 |
0 |
1 |
2 |
7 |
14 |
| Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation |
0 |
0 |
0 |
0 |
3 |
3 |
8 |
41 |
| Empirical economic analysis of orphan drug legislation impact on innovation |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
419 |
| Evolution des prescriptions de médicaments orphelins en cancérologie: en France et à l’échelle d’un établissement hospitalier |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
34 |
| Evolution des prescriptions de médicaments orphelins en cancérologie: en France, et à l’échelle d’un établissement hospitalier |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
16 |
| Exploring the historical roots of mesenchymal stem cell research using reference publication year spectroscopy |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
20 |
| Global overview of patenting landscape in unmanned aerial vehicles |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
46 |
| HTA National Public Policy and Their Socio-Economic Environment: A European Perspective |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
9 |
| Health Technology Assessment Agencies and their economic environment: a European perspective |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
15 |
| Health innovation for rare diseases |
0 |
0 |
0 |
0 |
1 |
1 |
7 |
14 |
| Impact de la législation européenne des médicaments orphelins sur le marché global du médicament |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
4 |
| Impact of Health Technology Assessment on Innovation Diffusion: the case of techniques in Interventional Radiology |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
46 |
| Impact of market exclusivity versus IP protection in fostering innovation for rare diseases |
0 |
0 |
0 |
0 |
5 |
5 |
6 |
17 |
| Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
7 |
| Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale |
0 |
0 |
0 |
0 |
2 |
2 |
4 |
10 |
| Intellectual Property Rights and Traditional Knowledge: to which extend biodiversity is preempted at the global level |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
12 |
| Le statut de médicament orphelin est un signal positif pour les investisseurs lors de l'introduction en bourse des sociétés de biotechnologie |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
| Les enjeux de la reconnaissance de la radiologie interventionnelle: un travail de recherche interdisciplinaire (sociologie, économie, droit) |
0 |
0 |
0 |
0 |
3 |
3 |
5 |
36 |
| L’histoire de la radiologie interventionnelle: développement et diffusion d’une innovation médicale |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
25 |
| Mapping scientific dynamics in « Regenerative Medicine » research |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
| Mapping scientific dynamics in « Regenerative Medicine » research, Tissue Engineering Part A, 21, S1 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
9 |
| Market Valuation of FDA Orphan Drug Regulatory Events |
0 |
0 |
0 |
0 |
3 |
3 |
5 |
78 |
| Medical literature imprinting by pharma ghost writing: a scientometric evaluation |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
12 |
| Médicaments orphelins et maladies rares sur Twitter |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
| Naissances de la radiologie interventionnelle. Le rôle de Charles T. Dotter |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
7 |
| Naming institution after neologism as marker of the institutionalization of new discipline |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
46 |
| Neologisms and affiliation name: a bibliometric perspective on the institutionalization of interventional radiology |
0 |
0 |
0 |
0 |
2 |
2 |
5 |
24 |
| Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies |
0 |
0 |
0 |
16 |
2 |
2 |
8 |
125 |
| Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021 |
0 |
0 |
0 |
0 |
3 |
3 |
6 |
14 |
| Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies |
0 |
0 |
0 |
0 |
3 |
3 |
8 |
26 |
| Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies |
0 |
0 |
0 |
0 |
1 |
1 |
11 |
57 |
| Orphan Drug Market Exclusivity Extension versus Patent Monopoly |
0 |
0 |
0 |
0 |
0 |
2 |
9 |
185 |
| Orphan Drug legislation: evaluation of the impact of market exclusivity extension |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
35 |
| Orphan Drugs: Why the US legislation approves more than the EU? |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
44 |
| Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
103 |
| Pourquoi les prix des traitements contre les maladies rares deviennent fous ? |
0 |
0 |
0 |
0 |
2 |
2 |
5 |
20 |
| R&D incentives and innovation spillovers: evidence from the European orphan drug regulation |
0 |
0 |
0 |
0 |
4 |
5 |
13 |
167 |
| Regulating the drugs market in the EU: the contradiction between safety, innovation and access to care |
0 |
0 |
0 |
0 |
1 |
5 |
10 |
32 |
| Schéma régional de l'enseignement supérieur, de la recherche & de l'innovation |
0 |
0 |
0 |
0 |
2 |
2 |
3 |
15 |
| Science and Technology Indicators of Microalgae-Based Biofuel Research |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
29 |
| Serendipity and university technology transfer: a case study |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
19 |
| Social Recognition of a Medical Innovation: the case of Interventional Radiology in Oncology |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
26 |
| The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
18 |
| The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
3 |
| The EU's Government of Pharmaceuticals: Incompleteness Embraced |
0 |
0 |
0 |
1 |
5 |
5 |
8 |
11 |
| The political construction of orphan drugs market: between innovation & access to care |
0 |
0 |
0 |
0 |
2 |
3 |
6 |
27 |
| The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
| Towards a Patent landscaping of Regenerative Medicine |
0 |
0 |
0 |
0 |
3 |
5 |
12 |
63 |
| Ultrasons focalisés de haute intensité: analyse des dynamiques d’innovations |
0 |
0 |
0 |
0 |
2 |
2 |
5 |
22 |
| Website: orphandrugseconomics.org |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
6 |
| Total Working Papers |
0 |
0 |
2 |
27 |
100 |
139 |
378 |
2,955 |
LogEc is hosted by the
Örebro University School of Business.